Abstract:The biodistribution of molecular imaging probes or tracers mainly depends on the chemical nature of the probe and the preferred metabolization and excretion routes. Small molecules have rather short half-lives while antibodies reside inside the organism for a longer period of time. An excretion via kidneys and bladder is faster than a mainly hepatobiliary elimination. To manipulate the biodistribution behavior of probes, different strategies have been pursued, including utilizing serum albumin as an inherent transport mechanism for small molecules. Here, we modified an existing small molecular fluorescent probe targeted to the endothelin-A receptor (ETAR) with three different albumin-binding moieties to search for an optimal modification strategy. A diphenylcyclohexyl (DPCH) group, a p-iodophenyl butyric acid (IPBA), and a fatty acid (FA) group were attached via amino acid linkers. All three modifications result in transient albumin binding of the developed compounds, as concluded from gel electrophoresis investigations. Spectrophotometric measurements applying variable amounts of bovine, murine, and human serum albumin (BSA, MSA, and HSA) reveal distinct variations of absorption and emission intensities and shifts of their maximum wavelengths. Binding to MSA results in the weakest effects, while binding to HSA leads to the strongest. Cell-based in vitro investigations utilizing ETAR-positive HT-1080 fibrosarcoma and ETAR-negative BT-20 breast adenocarcinoma cells support a retained specific target-binding capacity of the modified compounds and different degrees of unspecific binding. In vivo analysis of a HT-1080 xenograft model in nude mice over the course of 1 week by fluorescence reflectance imaging illustrates noticeable differences between the four examined probes. While the IPBA-modified probe shows the highest absolute signal intensity values, the FA-modified probe exhibits the most favorable tumor-to-organ ratios. In summary, reversible binding to albumin enhances the biological half-life of the designed probes substantially and enables near infrared optical imaging of subcutaneous tumors for several days in vivo. Because the unmodified probe already exhibits reasonable results, the attachment of albumin-binding moieties does not lead to a substantially improved imaging outcome in terms of target-to-background ratios. On the other hand, because the implemented transient albumin binding results in an overall higher amount of probe inside tumor lesions, this strategy might be adaptable for theranostic or therapeutic approaches in a future clinical routine.

Preparation and imaging study of a hepatic receptor imaging agent

Preparation and evaluation of mixed-mode resins with tryptophan analogues as functional ligands for human serum albumin separation☆

Preparation and Preliminary Evaluate of 99Tcm-Hynic-nga Complexes for Hepatic Asialoglycoprotein Receptor Imaging

Quantitation, Visualization, and Monitoring of Conformational Transitions of Human Serum Albumin by A Tetraphenylethene Derivative with Aggregation-Induced Emission Characteristics

Sodium Pump Na Plus /K Plus ATPase Subunit 1-Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models

Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma

Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA

Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin αvβ3 and CD13 for cancer therapy

Preparation and experimental study of a new renal imaging agent: N, N-BIS (2-aminoethyl) propane haxaacetic acid labeled with technitium-99m

[68Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport

Preliminary study of molecular imaging of human hepatocellular carcinoma xenograft with Gd-based MR probe containing arginine-glycine-aspartic acid chelate

Exploring the Influence of Different Albumin Binders on Molecular Imaging Probe Distribution

Preparation and Micropet Imaging of Somatostatin Receptor Antagonist 68 Ga-NOTA-JR11

Preliminary Study of Molecular Imaging of Human Hepatoceilular Carcinoma Xenoggaft with Gd-based MR Probe Containiug Arginine-Glycine-aspartic Acid Chelate

One-pot synthesis and biodistribution of fluorine-18 labeled serum albumin for vascular imaging

Synthesis, Preclinical Evaluation, and a Pilot Clinical Imaging Study of [18F]alf-Nota-jr11 for Neuroendocrine Neoplasms Compared with [68Ga]ga-Dota-tate.

Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models

Label and animal imaging studies of prostate specific membrane antigen molecular image probe 68Ga-PSMA11?

The imaging study of a small-molecular inhibitor targeting prostate speciifc membrane antigen

Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.